| Company | Date | Position | Consensus β | Price Target β | 1-Yr Return | vs S&P 500 β |
|---|---|---|---|---|---|---|
|
BBIO
BridgeBio Pharma
|
Oct 30, 2026 | BUY |
Strong Buy
+26.1% avg upside
36 analysts
|
$92.00
22.78% Upside
|
+2.5% | Β· |
|
PTCT
PTC Therapeutics
|
Oct 30, 2026 | BUY |
Buy
+35.4% avg upside
29 analysts
|
$90.00
50.12% Upside
|
+0.7% | Β· |
|
ALNY
Alnylam Pharma
|
Oct 30, 2026 | BUY |
Strong Buy
+76.3% avg upside
53 analysts
|
$329.00
99.30% Upside
|
-5.1% | Β· |
|
VKTX
Viking Therapeutics
|
Oct 29, 2026 | BUY |
Strong Buy
+172.0% avg upside
31 analysts
|
$94.00
244.54% Upside
|
+0.1% | Β· |
|
WVE
Wave Life Sciences
|
Oct 28, 2026 | BUY |
Strong Buy
+443.5% avg upside
30 analysts
|
$11.00
206.31% Upside
|
-22.0% | Β· |
|
REGN
Regeneron
|
Oct 16, 2026 | BUY |
Strong Buy
-12.2% avg upside
60 analysts
|
$978.00
5.30% Upside
|
+21.1% | Β· |
|
ASND
Ascendis Pharma
|
Oct 16, 2026 | BUY |
Strong Buy
+12.3% avg upside
29 analysts
|
$269.00
7.12% Upside
|
+20.4% | Β· |
|
IONS
Ionis Pharmaceuticals
|
Oct 16, 2026 | BUY |
Strong Buy
+74.1% avg upside
44 analysts
|
$88.00
102.31% Upside
|
-37.7% | Β· |
|
BMRN
BioMarin Pharmaceutical
|
Oct 15, 2026 | BUY |
Strong Buy
+63.6% avg upside
52 analysts
|
$88.00
50.48% Upside
|
+4.4% | Β· |
|
PRAX
Praxis Precision Medicines
|
Oct 15, 2026 | BUY |
Strong Buy
+99.2% avg upside
25 analysts
|
$706.00
146.94% Upside
|
+6.1% | Β· |
|
SLDB
Solid Biosciences
|
Oct 15, 2026 | BUY |
Strong Buy
+176.4% avg upside
26 analysts
|
$20.00
222.62% Upside
|
+8.5% | Β· |
|
CRSP
Crispr Therapeutics AG
|
Oct 15, 2026 | HOLD |
Buy
+45.6% avg upside
41 analysts
|
$52.00
1.23% Upside
|
-22.1% | Β· |
|
QURE
uniQure
|
Oct 15, 2026 | BUY |
Strong Buy
+121.1% avg upside
30 analysts
|
$48.00
93.32% Upside
|
-7.7% | Β· |
|
RARE
Ultragenyx Pharmaceutical
|
Oct 15, 2026 | HOLD |
Strong Buy
+193.8% avg upside
36 analysts
|
$16.00
0.60% Downside
|
+10.1% | Β· |
|
ARWR
Arrowhead Pharmaceuticals
|
Oct 15, 2026 | BUY |
Strong Buy
+26.6% avg upside
29 analysts
|
$109.00
81.99% Upside
|
-18.3% | Β· |
|
VYGR
Voyager Therapeutics
|
Mar 17, 2026 | BUY |
Strong Buy
+730.1% avg upside
23 analysts
|
β | -61.2% | Β· |
|
EDIT
Editas Medicine
|
Mar 17, 2026 | HOLD |
Buy
+398.6% avg upside
33 analysts
|
β | -25.6% | Β· |
|
VRTX
Vertex Pharmaceuticals
|
Mar 11, 2026 | BUY |
Strong Buy
-20.5% avg upside
62 analysts
|
$525.00
5.97% Downside
|
+8.5% | Β· |
|
ANAB
AnaptysBio
|
Mar 09, 2026 | HOLD |
Strong Buy
+48.7% avg upside
26 analysts
|
$50.00
3.66% Upside
|
+14.6% | Β· |
|
CORT
Corcept Therapeutics
|
Mar 02, 2026 | BUY |
Buy
-17.9% avg upside
16 analysts
|
β | +94.8% | Β· |
|
NTLA
Intellia Therapeutics
|
Mar 02, 2026 | BUY |
Buy
+187.2% avg upside
39 analysts
|
β | -36.7% | Β· |
|
ALKS
Alkermes
|
Feb 26, 2026 | BUY |
Strong Buy
-3.4% avg upside
34 analysts
|
β | +47.7% | Β· |
|
JAZZ
Jazz Pharmaceuticals
|
Feb 25, 2026 | BUY |
Strong Buy
+16.2% avg upside
36 analysts
|
β | +16.4% | Β· |
|
AXSM
Axsome Therapeutics
|
Feb 24, 2026 | BUY |
Strong Buy
+63.9% avg upside
30 analysts
|
β | -20.0% | Β· |
|
RAPP
Rapport Therapeutics, Inc.
|
Nov 10, 2025 | BUY |
Strong Buy
+158.1% avg upside
15 analysts
|
β | +4.2% | Β· |
|
LRMR
Larimar Therapeutics
|
Nov 06, 2025 | BUY |
Strong Buy
+621.1% avg upside
22 analysts
|
β | -31.1% | Β· |
|
TSHA
Taysha Gene Therapies
|
Nov 05, 2025 | BUY |
Strong Buy
+241.9% avg upside
22 analysts
|
β | +1.5% | Β· |
|
ARGX
Argenx Se
|
Aug 01, 2025 | BUY |
Strong Buy
-8.2% avg upside
48 analysts
|
β | +26.7% | Β· |
|
KROS
Keros Therapeutics
|
Dec 04, 2024 | BUY |
Strong Buy
+116.6% avg upside
21 analysts
|
β | -70.1% | Β· |
|
CRMD
Cormedix
|
Nov 14, 2023 | BUY |
Strong Buy
+165.8% avg upside
13 analysts
|
$18.00
216.06% Upside
|
+251.4% | Β· |
|
ARVN
Arvinas Holding Company
|
Jan 17, 2023 | BUY |
Buy
+257.9% avg upside
28 analysts
|
$65.00
727.02% Upside
|
+11.1% | Β· |
|
RLMD
Relmada Therapeutics
|
Dec 08, 2022 | HOLD |
Buy
+273.3% avg upside
15 analysts
|
$4.00
11.77% Upside
|
+18.0% | Β· |
|
KRSA
Korsana Biosciences
|
May 05, 2022 | BUY |
Strong Buy
+27.8% avg upside
7 analysts
|
$14.00
53.58% Downside
|
-60.1% | Β· |
|
ELOX
Eloxx Pharmaceuticals
|
Aug 08, 2019 | BUY |
Strong Buy
+168.9% avg upside
13 analysts
|
$10.00
25.57% Downside
|
Β· | Β· |
|
ABEO
Abeona Therapeutics
|
Jun 19, 2019 | BUY |
Strong Buy
+295.1% avg upside
18 analysts
|
$20.00
359.72% Upside
|
Β· | Β· |
|
SRPT
Sarepta Therapeutics
|
Aug 08, 2014 | BUY |
Buy
+223.8% avg upside
50 analysts
|
β | +53.8% | Β· |
|
ACAD
ACADIA Pharmaceuticals
|
Aug 07, 2014 | BUY |
Strong Buy
+71.5% avg upside
43 analysts
|
$33.00
60.32% Upside
|
+86.9% | Β· |
|
TLPH
Talphera
|
Jul 28, 2014 | BUY |
Buy
+357.6% avg upside
15 analysts
|
$14.00
1259.28% Upside
|
Β· | Β· |
Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.